TD Asset Management Inc Sells 45,407 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• TD Asset Management Inc reduced its stake in Alnylam Pharmaceuticals by 9.3%, selling 45,407 shares during the second quarter, now owning around 0.34% of the company.
• Alnylam's stock is seeing positive analyst reviews, with 24 buy ratings and recent price targets raised by firms such as Bank of America and Canaccord Genuity.
• The company reported strong quarterly earnings, with a net revenue of $773.69 million, exceeding analyst expectations and reflecting a 17.3% increase from the previous year.

TD Asset Management Inc lessened its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 9.3% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 441,177 shares of the biopharmaceutical company's stock after selling 45,407 shares during the quarter. TD Asset Management Inc owned about 0.34% of Alnylam Pharmaceuticals worth $143,863,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in ALNY. Brighton Jones LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $243,000. GAMMA Investing LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 14.3% during the 1st quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company's stock valued at $166,000 after acquiring an additional 77 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 14.6% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 14,404 shares of the biopharmaceutical company's stock valued at $3,889,000 after acquiring an additional 1,838 shares during the last quarter. QRG Capital Management Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 97.9% during the 1st quarter. QRG Capital Management Inc. now owns 1,949 shares of the biopharmaceutical company's stock valued at $526,000 after acquiring an additional 964 shares during the last quarter. Finally, Blue Trust Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 33.9% during the 1st quarter. Blue Trust Inc. now owns 1,158 shares of the biopharmaceutical company's stock valued at $313,000 after acquiring an additional 293 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on ALNY shares. Canaccord Genuity Group raised their price target on shares of Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the company a "buy" rating in a report on Friday, August 1st. Wall Street Zen downgraded shares of Alnylam Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Sunday. JPMorgan Chase & Co. dropped their price objective on shares of Alnylam Pharmaceuticals from $475.00 to $473.00 and set an "overweight" rating on the stock in a report on Monday. Bank of America raised their price objective on shares of Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the stock a "buy" rating in a report on Wednesday, September 17th. Finally, Truist Financial assumed coverage on shares of Alnylam Pharmaceuticals in a report on Monday, July 21st. They issued a "buy" rating and a $385.00 price objective on the stock. Twenty-four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $457.08.

Alnylam Pharmaceuticals Price Performance

NASDAQ ALNY opened at $469.36 on Wednesday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $484.21. The stock has a market cap of $61.52 billion, a price-to-earnings ratio of -190.02 and a beta of 0.36. The company's 50 day moving average is $453.28 and its two-hundred day moving average is $348.35. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company had revenue of $773.69 million for the quarter, compared to analysts' expectations of $633.54 million. During the same quarter last year, the business earned ($0.13) EPS. The firm's revenue was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Pushkal Garg sold 3,022 shares of the firm's stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $451.48, for a total transaction of $1,364,372.56. Following the sale, the executive vice president owned 20,221 shares in the company, valued at approximately $9,129,377.08. This trade represents a 13.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Yvonne Greenstreet sold 8,924 shares of the firm's stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $4,034,094.20. Following the sale, the chief executive officer owned 65,409 shares in the company, valued at approximately $29,568,138.45. The trade was a 12.01% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 98,144 shares of company stock worth $44,160,261 in the last 90 days. Insiders own 1.20% of the company's stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.